Further analysis indicated that body mass index ≥ 24 kg/m2 (HR 0.72 [95% CI 0.75–0.93]; p = 0.014) and history of hypertension (HR 1.35 [95% CI 1.01–1.79]; p = 0.037) may interfere with the therapeutic effects of PD‐1 with comparable safety profiles, which renewed personalized immunotherapy options for NSCLC patients in clinical settings. Here, PDCD1 is linked to hypertensive disorder.